Abstract:Background A severe deficiency of ADAMTS13 activity contributes to the pathogenesis of thrombotic thrombocytopenic purpura (TIP). Measuring the activity of ADAMTS13 is helpful for the diagnosis of UP and the prognostic monitor in TIP patients. Most available assays are cumbersome and costly, so not easily adapted to routine laboratories. ADAMTS13 cleaves von Willebrand factor (VWF) within the domain A2, located between domains Al and A3. Therefore, specific assays for ADAMTS13 activity could be based on the different structures of VWF before and after the cleavage. Using this hypothesis we try to establish a new and simple method to determine ADAMTS13 activity.Methods First, plasma samples were exposed in denaturing condition to allow cleavage of VWF by ADAMTS13. Then, the ADAMTS13 activity was measured with two novel monoclonal antibodies, SZ-129 and SZ-125, which specifically recognize the VWF Al and A3 domains by using a two-site sandwich ELISA. Compared with a residual-collagen binding assay (R-CBA), plasma ADAMTS13 activities in 161 samples were assessed, and the inhibitory activities of ADAMTS13 autoantibody in 24 TIP patients were determined. The relationship of these two assays was analyzed by linear correlation, and the sensitivity and specificity of the new assay was also evaluated.Results Plasma ADAMTS13 activities in normal people and TIP, acute myocardial infarction (AMI), and idiopathic thrombocytopenic purpura (ITP) patients determined by the new assay were (89.75 +/- 7.93)%, (17.63 +/- 18.71)%, (68.55 +/- 18.08)%, (85.83 +/- 9.84)%, respectively. Results were consistent with those of R-CBA, the squared correlation factor was 0.9183 of the two assays. The new assay can easily discriminate a UP plasma sample from a non-TIP plasma sample (P <0.01), and the coefficient of variation for the new assay was 6.17%. In 23 idiopathic UP patients, the inhibitor activity of ADAMTS13 autoantibody ranged from 12% to 100%, while no inhibitory activity was detected in one hereditary UP patient.Conclusion This new and simple assay for ADAMTS13 activity could be used routinely in the clinic to determine the activity of ADAMTS13. Chin Med J 2010;123(14):1859-1863

Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw–Schulman syndrome

[Identification of Two Novel Mutations in ADAMTS13 Gene in a Patient with Hereditary Thrombotic Thrombocytopenic Purpura].

Genetic and Functional Characterization of ADAMTS13 Variants in a Patient Cohort with Upshaw-Schulman Syndrome Investigated in Germany

Novel ADAMTS13 Mutation in a Family with Three Recurrent Neonatal Deaths: a Case Report and Literature Review

Hereditary Thrombotic Thrombocytopenic Purpura in a Chinese Boy With a Novel Compound Heterozygous Mutation of the ADAMTS13 Gene

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

The Highs and Lows of ADAMTS13 Activity

Association of Serum ADAMTS7 Levels and Genetic Variant Rs1994016 with Acute Coronary Syndrome in a Chinese Population: A Case Control Study.

Linear relationship between ADAMTS13 activity and platelet dynamics even before severe thrombocytopenia

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

Excessive cleavage of von Willebrand factor multimers by ADAMTS13 may predict the progression of transplant-associated thrombotic microangiopathy

Therapy of Hereditary Ttp with Adamts13 Deficiency - A Case Report and Review of the Literature.

Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond

Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis

Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura

[Advances in the treatment of thrombotic thrombocytopenic purpura]

Evaluation and Clinical Application of A New Method for Detecting Adamts13 Activity

[Developments of high-throughput sequencing-based diagnosis of congenital thrombocytopenia/platelet disorders in a registry study]

Genetic Variation of Aggrecanase-2 (ADAMTS5) in Susceptibility to Osteoarthritis

Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura